Back to News
Market Impact: 0.3
IASO Bio Hosts FUCASO Singapore Launch Event, Marking the Official Commercial Landing of China's Original Fully Human BCMA CAR-T Cell Therapy in Southeast Asia's Healthcare Hub
Source: PR Newswire
Healthcare & BiotechProduct LaunchesTechnology & Innovation
IASO Bio and Singapore partner Pills and Pokes held a launch event on November 3, marking FUCASO’s commercial arrival in Singapore. The article describes it as the world’s first fully human BCMA-targeted CAR-T cell therapy and says it was approved by Singapore’s Health Sciences authority.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- What Wall Street billionaires are saying about Democrats' midterm sweep
- A blue wave sends futures into the green
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- China Blocks SoftBank Acquisition of ABB Robot Unit, FT Says
- After the midterms, a bigger clash over data centers could be coming
- Inside the chip talent war: Trade secrets and rising Chinese rivals